articl
describ
design
synthesi
activ
evalu
glycomimet
dcsign
antagonist
use
mannos
residu
anchor
protein
carbohydr
recognit
domain
crd
molecul
design
structur
known
pseudomannobiosid
antagonist
includ
addit
hydrophob
group
expect
engag
lipophil
area
dcsign
crd
result
demonstr
synthes
compound
potent
inhibit
dcsignmedi
adhes
mannan
coat
plate
addit
silico
dock
studi
perform
ration
result
suggest
optim
onlin
version
articl
tolllik
receptor
manlam
mannosyl
lipoarabinomannan
tmsotf
trimethylsilyl
triflat
introduct
immatur
dendrit
cell
dc
firstlin
guard
variou
pathogen
invad
peripher
tissu
bind
pathogen
differenti
matur
dc
present
antigen
particl
cell
dcsign
dendrit
cellspecif
intercellular
adhes
molecul
nonintegrin
specif
ctype
lectin
recogn
pathogencel
surfac
glycoprotein
probabl
first
transmembran
receptor
immatur
dc
encount
invad
pathogen
bind
vast
number
divers
pathogenassoci
molecular
pattern
pamp
normal
bind
event
trigger
intern
dcsignpathogen
complex
follow
pathogen
lysosom
degrad
conjug
result
fragment
mhcii
initi
adapt
immun
respons
cell
addit
dcsign
serv
signal
receptor
mediat
pathogeninduc
tolllik
receptor
tlr
signal
turn
modifi
dc
matur
therefor
intens
adapt
immun
respons
pathogen
howev
report
take
advantag
mechan
appear
deter
dc
matur
dcsignmedi
signal
inhibit
antigen
present
cell
van
kooyk
group
shown
enter
dc
via
dcsign
avoid
lytic
degrad
escap
host
immun
system
also
present
directli
cell
enabl
fulli
dissemin
infect
pathogen
also
believ
use
principl
host
invas
thu
inhibit
pathogen
interact
dcsign
specif
antagonist
consid
plausibl
concept
new
antiinfect
agent
sever
group
recent
demonstr
inhibit
dcsign
either
design
glycoconjug
antibodi
prevent
pathogen
attach
dc
inhibit
infect
immun
cell
earliest
step
dcsign
specif
bind
mannos
fucoseglycosyl
endogen
protein
well
mannosyl
pamp
tuberculosi
manlam
other
moreov
mannoseand
fucosecontain
oligosaccharid
lewisx
bind
dcsign
moder
high
affin
man
fuc
weak
affin
consequ
glycomimet
structur
design
inhibit
dcsign
base
oligomannosid
lewisx
previou
studi
concentr
design
synthesi
monoval
glycoconjug
glycomimet
dcsign
antagonist
molecul
fig
conceiv
metabol
stabl
nativ
oligosaccharid
andor
equip
reactiv
moieti
enabl
multimer
present
multival
support
ligand
moder
weak
affin
dcsign
compar
slightli
superior
start
oligosaccharid
templat
therebi
display
limit
therapeut
potenti
monomer
form
howev
present
multimer
form
effect
inhibitor
dcsignmedi
viral
infect
inde
pseudotrisaccharid
mimick
linear
found
inhibit
dcsign
bind
mannosyl
bsa
ic
surfaceplasmon
resonancespr
present
tetraval
dendron
also
found
inhibit
tran
infect
lymphocyt
hiv
low
micromolar
concentr
improv
bind
affin
monoval
glycoconjug
design
mannosebas
glycoconjug
deriv
could
bind
new
bind
area
dcsign
carbohydr
recognit
domain
crd
occupi
nativ
ligand
ligand
candid
synthes
affin
dcsign
evalu
vitro
assay
measur
inhibit
dcsignmedi
immatur
dendrit
cell
adhes
mannanco
plate
addit
dock
studi
perform
ration
result
suggest
optim
assay
data
demonstr
effort
design
synthes
mannosebas
dcsign
antagonist
result
compound
potent
inhibit
dcsignmedi
adhes
mannanco
plate
potenti
prevent
dcsignmedi
pathogen
recognit
dc
silico
molecular
dock
studi
molecul
tabl
built
chembiodraw
ultra
ligand
geometri
optim
chembio
ultra
use
forc
field
minimum
rm
gradient
reach
optim
structur
refin
gamess
interfac
use
semiempir
method
qa
optim
algorithm
gasteig
charg
atom
step
carboxyl
nonaromat
amin
kept
ioniz
state
ph
crystal
structur
dcsign
crd
chain
aminoacid
sequenc
complex
man
pdb
code
taken
startingpoint
ligand
man
taken
refer
structur
area
around
consid
activ
site
crystal
structur
clean
flexx
delet
ligand
man
crystallograph
water
molecul
hydrogen
automat
ad
heavi
atom
two
water
molecul
hoh
residu
flexx
preserv
freeli
rotat
water
dock
studi
sinc
one
flexx
id
stabil
interact
residu
receptor
one
id
stabil
man
bind
conform
addit
pharmmet
pharmacophor
spheric
coordin
around
ca
defin
correctli
account
complex
interact
ca
residu
sidechain
aspart
glutam
lysin
arginin
residu
kept
ioniz
state
ph
flexx
molecular
dock
program
structurebas
design
use
ligand
dock
use
standard
triangl
algorithm
place
base
fragment
paramet
flexx
modifiedoptim
dock
studi
clash
handl
b
maximum
number
solut
per
iter
c
maximum
number
solut
per
fragment
propos
bind
mode
highest
rank
dock
antagonist
evalu
use
final
score
rmsd
tool
explor
rel
structur
differ
propos
bind
mode
graphic
represent
propos
bind
posit
molecul
obtain
use
accelri
discoveri
studio
dock
procedur
abl
correctli
predict
bind
orient
molecul
pdb
databas
ie
crystal
structur
ligand
complex
protein
attempt
reproduc
pose
man
seen
xray
complex
target
dcsign
crd
top
dock
pose
within
root
mean
squar
deviat
rmsd
crystal
structur
residu
man
predict
top
score
pose
one
best
fit
crystal
structur
man
overlap
reason
well
fig
gener
dichloromethan
methanol
n
ndiisopropylethylamin
triethylamin
dri
calcium
hydrid
thf
distil
sodium
n
ndimethylacetamid
dma
dri
activ
molecular
siev
reaction
requir
anhydr
condit
perform
nitrogen
h
c
fnmr
spectra
record
mhz
bruker
instrument
chemic
shift
h
c
spectra
express
ppm
rel
intern
si
standard
signal
abbrevi
singlet
bs
broad
singlet
doublet
triplet
q
quartet
multiplet
sugar
signal
number
customari
cyclohexan
proton
indic
letter
follow
number
number
cyclohexan
ring
compound
unconvent
see
figur
si
supplementari
inform
file
adopt
facilit
comparison
nativ
disaccharid
mass
spectra
obtain
thermofish
lcq
apparatu
esi
ioniz
iontrap
esi
esquir
bruker
microflex
apparatu
maldi
ioniz
bruker
apex
ii
icr
ftm
esi
ionizationhrm
specif
optic
rotat
valu
measur
use
perkinelm
nm
dm
cell
thin
layer
chromatographi
tlc
carri
precoat
merck
f
silica
gel
plate
flash
chromatographi
fc
carri
machereynagel
silica
gel
mesh
compound
describ
synthesi
gener
procedur
synthesi
amid
anilid
describ
character
compound
report
supplementari
inform
acid
bispentafluorophenylest
coopfp
coopfp
mg
mmol
eq
ad
solut
diacid
mg
mmol
eq
dri
thf
ml
stir
nitrogen
atmospher
min
pentafluorophenol
mg
mmol
eq
ad
solut
stir
room
temperatur
h
complet
reaction
solvent
evapor
reduc
pressur
residu
dissolv
et
organ
phase
wash
hcl
satur
na
co
dri
sodium
sulphat
solvent
evapor
reduc
pressur
yield
mg
yield
pure
colourless
oil
c
chcl
mcpba
ad
mg
mmol
eq
solut
pfp
ester
mg
mmol
eq
dri
ch
cl
ml
stir
reaction
stir
nitrogen
room
temperatur
tlc
hexan
etoac
show
disappear
start
materi
solvent
evapor
reduc
pressur
reaction
mixtur
dilut
etoac
wash
satur
nahco
water
organ
phase
dri
sodium
sulphat
solvent
evapor
reduc
pressur
yield
mg
crude
product
purifi
flash
chromatographi
hex
etoac
afford
mg
pure
allyl
alcohol
ml
mmol
eq
cu
otf
mg
mmol
eq
ad
solut
epoxid
mg
mmol
eq
minimum
amount
dri
ch
cl
stir
nitrogen
solut
stir
room
temperatur
complet
ca
h
tlc
toluen
etoac
reaction
mixtur
directli
purifi
flash
chromatographi
toluen
etoac
yield
mg
yield
pure
product
yellow
oil
mixtur
acceptor
mg
mmol
eq
donor
mg
mmol
eq
coevapor
toluen
three
time
powder
acid
wash
molecular
siev
ad
mixtur
kept
vacuum
hour
dissolv
dri
ch
cl
ml
cool
c
tmsotf
mmol
eq
ad
reaction
mixtur
stir
reaction
monitor
tlc
toluen
etoac
hexan
etoac
finish
min
reaction
quench
et
n
mixtur
warm
room
temperatur
filter
celit
pad
filtrat
evapor
reduc
pressur
crude
product
purifi
flash
chromatographi
c
c
c
c
c
c
c
c
c
c
c
c
c
c
amin
eq
ad
pfpscaffold
eq
dri
thf
stir
nitrogen
atmospher
room
temperatur
complet
tlc
hexan
etoac
chcl
meoh
solvent
evapor
reduc
pressur
crude
product
purifi
use
three
consecut
ml
isolut
hmn
column
condit
hcl
naoh
water
final
dissolv
ml
etoac
elut
gravimetr
organ
phase
collect
solvent
evapor
reduc
pressur
obtain
pure
product
directli
deprotect
use
follow
gener
procedur
solut
bisamid
eq
dri
methanol
nitrogen
room
temperatur
solut
sodium
methoxid
meoh
eq
ad
reaction
complet
tlc
chcl
meoh
reaction
mixtur
dilut
methanol
neutral
prewash
amberlit
ira
resin
filter
solvent
evapor
reduc
pressur
crude
purifi
flash
chromatographi
chcl
meoh
trimethylsilylethanol
ml
mmol
eq
dmap
mg
mmol
eq
ad
solut
diacid
g
mmol
eq
dri
ch
cl
ml
stir
separ
dcc
g
mmol
eq
dissolv
ch
cl
ml
solut
ad
dropwis
previou
one
cool
c
stir
min
reaction
mixtur
warm
room
temperatur
stir
h
reaction
complet
tlc
hexan
etoac
reaction
mixtur
dilut
ch
cl
filter
celit
pad
solvent
evapor
reduc
pressur
product
purifi
flash
chromatographi
hexan
etoac
obtain
g
yield
pure
cooch
ch
tm
cooch
ch
tm
mcpba
ad
g
mmol
eq
solut
trimethylsilylethyl
ester
g
mmol
eq
dri
ch
cl
ml
stir
reaction
stir
nitrogen
room
temperatur
complet
reaction
h
tlc
toluen
etoac
reaction
mixtur
dilut
ch
cl
wash
satur
nahco
water
organ
phase
dri
sodium
sulphat
solvent
evapor
reduc
pressur
obtain
g
crude
product
purifi
flash
chromatographi
hexan
etoac
acoh
yield
g
yield
pure
product
cu
otf
mg
mmol
eq
ad
solut
epoxid
g
mmol
eq
allyl
alcohol
ml
mmol
eq
stir
nitrogen
atmospher
solut
stir
room
temperatur
reaction
complet
h
tlc
toluen
etoac
reaction
mixtur
dilut
et
wash
nh
satur
nh
cl
satur
nh
cl
organ
phase
dri
sodium
sulphat
solvent
evapor
reduc
pressur
crude
product
purifi
flash
chromatographi
toluen
etoac
yield
g
yield
pure
product
mixtur
acceptor
mg
mmol
eq
donor
mg
mmol
eq
coevapor
toluen
three
time
powder
acid
wash
molecular
siev
ad
mixtur
kept
vacuum
hour
dissolv
dri
ch
cl
ml
cool
c
tmsotf
mmol
eq
ad
reaction
mixtur
stir
reaction
stir
temperatur
monitor
tlc
toluen
etoac
chcl
aceton
min
reaction
quench
ad
net
mixtur
warm
room
temperatur
filter
celit
pad
filtrat
evapor
reduc
pressur
product
purifi
flash
chromatographi
toluen
etoac
yield
mg
solut
diacid
eq
dri
dma
hatu
eq
appropri
anilin
eq
ad
stir
nitrogen
atmospher
room
temperatur
reaction
mixtur
warm
c
disappear
start
materi
tlc
chcl
meoh
chcl
aceton
anoth
aliquot
hatu
eq
anilin
eq
ad
stir
reaction
stir
c
day
reaction
complet
solvent
evapor
reduc
pressur
product
purifi
membran
filtrat
use
isolut
phase
separ
column
therefor
crude
reaction
product
dissolv
ch
cl
ml
charg
onto
column
hcl
ml
organ
phase
elut
charg
onto
anoth
column
contain
naoh
organ
phase
dri
sodium
sulphat
solvent
evapor
reduc
pressur
crude
purifi
flash
chromatographi
chcl
meoh
yield
anilid
deprotect
use
follow
procedur
solut
sodium
methoxyd
eq
meoh
ad
solut
bisanilid
eq
dri
methanol
stir
nitrogen
atmospher
room
temperatur
reaction
complet
tlc
toluen
aceton
reaction
mixtur
dilut
methanol
neutral
prewash
amberlit
ira
resin
filter
solvent
evapor
reduc
pressur
crude
anilid
purifi
flash
chromatographi
chcl
meoh
buffi
coat
venou
blood
normal
healthi
volunt
obtain
blood
transfus
centr
slovenia
accord
institut
guidelin
studi
approv
nation
medic
ethic
committe
ministri
health
republ
slovenia
written
consent
obtain
collect
specimen
peripher
blood
mononuclear
cell
isol
use
lympholyt
h
cedarlan
laboratori
ontario
canada
cell
wash
twice
dulbecco
phosphatebuff
salin
dpb
count
use
sourc
immunomagnet
isol
cell
miltenyi
biotec
gmbh
bergisch
gladbach
germani
cultur
rpmi
cambrex
medium
supplement
fetal
bovin
serum
fb
gentamicin
gibco
paisley
uk
uml
rhgmcsf
uml
gentaur
pari
franc
day
half
medium
exchang
start
quantiti
rhgmcsf
uml
uml
day
nonadher
immatur
dc
harvest
character
flow
cytometri
hi
low
hla
dr
low
data
shown
cell
count
resuspend
medium
contain
uml
rhgmcsf
ngml
lp
cultur
day
well
cultur
plate
nunc
nunclon
surfac
nunc
maxisorp
precoat
mannan
mgml
sigma
carbon
buffer
ph
overnight
c
well
wash
pb
incub
bsa
pb
min
room
temperatur
variou
volum
mm
stock
solut
ligand
ad
well
obtain
requir
final
concentr
assay
pb
dmso
use
control
immatur
dc
harvest
wash
pb
label
carboxyfluorescein
succinimidyl
ester
cfse
accord
manufactur
protocol
molecular
probe
invitrogen
eugen
usa
resuspend
medium
contain
uml
rhgmcsf
either
uml
ngml
lp
concentr
ml
immatur
dc
suspens
ad
well
cell
allow
attach
min
well
wash
twice
pb
lysi
buffer
mm
tri
sd
ad
experi
done
quadrupl
concentr
antagonist
use
control
cell
estim
total
immatur
dc
ad
well
one
quadrupl
well
wash
pb
lysi
buffer
ad
directli
cfse
colourless
nonfluoresc
acet
group
cleav
intracellular
esteras
yield
highli
fluoresc
carboxyfluorescein
succinimidyl
ester
react
intracellular
amin
form
fluoresc
conjug
fluoresc
measur
nm
tecan
saphir
micropl
reader
tecan
group
maennedorf
switzerland
excit
wavelength
nm
directli
proport
number
adher
cell
cell
adher
determin
eq
tx
totaldc
fluoresc
cfse
determin
cell
wash
differ
time
dendrit
cell
blank
background
fluoresc
buffer
ic
valu
calcul
fit
mean
valu
dcsignmedi
cell
adher
versu
log
antagonist
concentr
logist
sigmoid
equat
nonlinear
leastsquar
curvefit
use
originpro
softwar
experiment
data
present
standard
error
bar
control
experi
perform
known
dcsign
antagonist
two
dcsign
specif
antibodi
order
prove
dcsign
specif
inhibit
structurebas
design
substitut
mimic
tuberculosi
number
pathogen
includ
virus
hcv
cmv
dengu
ebola
sarscov
hsv
coronavirus
west
nile
viru
measl
viru
bacteria
helicobact
pylori
leptospira
interrogan
bind
dcsign
mannosyl
glycoprotein
manlam
improv
bind
affin
mannosebas
glycoconjug
explor
known
crystal
structur
dcsign
carbohydraterecognit
domain
crd
complex
tetramannosid
man
pdb
code
search
bind
site
dcsign
crd
whose
bind
potenti
entir
exploit
mimic
design
far
primari
interact
oligosaccharid
occur
coordin
nonreduc
end
residu
oligosaccharid
ca
bind
site
expos
surfac
protein
shown
blue
sphere
fig
examin
crystal
structur
allow
identif
two
structur
featur
dcsign
crd
favour
site
increas
overal
free
energi
bind
hydrophob
region
defin
phenyl
ring
phe
fig
interact
weakli
residu
man
postul
phe
play
doubl
role
bind
mode
branch
mannosid
increas
affin
albeit
weakli
form
part
surfac
complementari
shape
moieti
man
allow
access
outer
arm
branch
trimannos
structur
prevent
bind
mannosid
n
link
glycan
core
branch
trimannos
structur
residu
interact
receptor
rather
point
away
protein
allow
bind
highmannos
oligosaccharid
hydrophob
cavityarea
behind
fig
also
like
interact
region
make
contact
residu
base
observ
sought
modifi
structur
pseudodisaccharid
fig
includ
fragment
capabl
interact
one
possibl
propos
bind
site
interact
dcsign
studi
nmr
spectroscopi
suggest
ligand
anchor
dcsign
crd
complex
ca
bind
site
man
nose
residu
inde
preliminari
dock
studi
confirm
hypothesi
suggest
cyclohexan
ring
may
extend
toward
phe
region
protein
bind
site
henc
addit
lipophil
fragment
could
ad
framework
exploit
carboxi
group
append
cyclohexan
ring
fig
identif
hydrophob
contact
proxim
bind
site
oligosaccharid
addit
lipophil
fragment
sugar
core
often
appli
improv
affin
glycomimet
dock
model
use
predict
requir
allow
select
amid
residu
virtual
screen
small
librari
substitut
aromat
nonaromat
deriv
gener
structur
therefor
prepar
fig
tabl
look
initi
structureact
relationship
sar
data
preliminari
spr
studi
show
tertiari
amid
affin
dcsign
mostli
secondari
amid
synthes
one
tertiari
amid
compound
tabl
test
present
studi
synthet
approach
use
shown
scheme
two
differ
condens
strategi
employ
synthes
amid
anilid
preform
pseudodisaccharid
respect
turn
obtain
appropri
modif
sequenc
previous
describ
synthesi
start
enantiomer
pure
acid
synthesi
amid
pentafluorophenyl
ester
could
use
protect
group
carboxyl
acid
first
four
step
exploit
activ
ester
reaction
intermedi
appropri
amin
thu
dipfpest
treat
mcpba
give
epoxid
condit
reaction
anilin
afford
monoanilid
product
along
recov
start
materi
thu
differ
strategi
implement
synthesi
anilid
start
trimethylsilylethyl
ester
scheme
elabor
describ
afford
correspond
pseudodisaccharid
ester
deprotect
trifluoroacet
acid
ch
cl
afford
acid
transform
anilid
reaction
excess
appropri
anilin
molequiv
n
n
n
n
tetramethyluronium
hexafluorophosph
hatu
follow
care
devis
addit
protocol
see
experiment
crude
compound
membran
filtrat
workup
see
experiment
chromatograph
deprotect
zemplen
condit
afford
anilid
activ
ligand
candid
test
use
assay
recent
describ
measur
abil
molecul
inhibit
dendrit
cell
adhes
mannanco
plate
see
experiment
detail
assess
whether
assay
identifi
inhibitor
dcsignmedi
adhes
adhes
measur
presenc
differ
concentr
dcsign
specif
antibodi
ic
valu
determin
tabl
result
demonstr
dc
adhes
mannanco
plate
abolish
dcsign
specif
antibodi
supplementari
data
ic
determin
two
antibodi
respect
presenc
monoclon
block
antibodi
maximum
inhibit
dc
adhes
high
confirm
assay
detect
dcsign
specif
antagonist
polyclon
block
antibodi
direct
dcsign
neck
region
amino
acid
rather
crd
like
antibodi
allow
maximum
inhibit
ca
reduc
dcsignmedi
adhes
steric
interfer
mannanco
surfac
note
neither
antibodi
allow
achiev
inhibit
adhes
suggest
dc
adhes
mannanco
plate
reli
sole
dcsign
also
exploit
dc
express
mannosebind
receptor
nonetheless
assay
serv
preliminari
screen
bind
inhibitor
candid
furthermor
compound
use
posit
control
found
inhibit
dc
adhes
ic
tabl
correspond
well
ic
obtain
spr
ic
preliminari
singlepoint
test
use
identifi
candid
ic
measur
synthes
compound
test
concentr
mm
assess
inhibit
immatur
dendrit
cell
adhes
fig
compound
exhibit
least
inhibit
cell
adhes
residu
adhes
mm
concentr
test
doserespons
ic
valu
determin
base
cutoff
valu
compound
chosen
ic
determin
addit
compound
precipit
preliminari
test
appar
visual
inspect
compound
exclud
test
ic
valu
determin
compound
tabl
origin
bind
data
report
supplementari
inform
highest
inhibitori
potenc
observ
compound
although
maxim
inhibit
observ
compound
adhes
similar
albeit
slightli
less
potent
inhibit
observ
compound
result
strongli
indic
major
substitu
select
reason
increas
potenc
dcsign
antagonist
compar
start
compound
inhibit
dc
adhes
weakli
fig
ligand
also
found
potent
pseudotrisaccharid
order
magnitud
sinc
amid
bear
simpl
benzyl
moieti
compound
carri
phenyl
lipophil
group
tabl
conclud
simpl
aromat
ring
without
small
substitu
optim
strong
interact
dcsign
strongli
suggest
addit
bind
affin
dcsign
may
attribut
primarili
hydrophob
interact
confirm
preliminari
hypothesi
assay
use
articl
measur
influenc
antagonist
bind
dc
mannanco
plate
sinc
immatur
dendrit
cell
express
variou
mannos
bind
lectin
difficult
distinguish
contribut
differ
lectin
adhes
process
howev
abil
dcsign
specif
antibodi
reduc
adhes
suggest
dcsign
major
determin
bind
abil
mannanco
plate
therefor
assay
serv
preliminari
screen
interest
candid
iden
tifi
approach
examin
activ
specif
use
assay
base
isol
dcsign
propos
bind
mode
synthes
mannosebas
dcsign
antagonist
expect
bind
mode
predict
flexx
molecular
dock
tool
shown
fig
similar
pose
obtain
ligand
analyz
strong
quantit
correl
found
calcul
score
experiment
inhibitori
concentr
conform
propos
flexx
show
markedli
consist
bind
mode
mannos
residu
dock
compound
ident
residu
crystal
structur
dcsign
crd
apart
residu
flexx
predict
two
princip
bind
mode
diamid
part
molecul
first
bind
mode
depict
compound
fig
lipophil
residu
stretch
toward
hydrophob
caviti
behind
phe
point
residu
aminoacid
residu
right
bottom
figur
fig
second
bind
mode
depict
compound
lipophil
residu
embrac
phe
predict
bind
mode
includ
interact
least
one
target
lipophil
site
could
explain
increas
affin
dcsign
furthermor
predict
bind
mode
indic
improv
bind
affin
might
obtain
exploit
addit
interact
instanc
guanidin
search
potent
monoval
dcsign
antagonist
taken
advantag
known
crystal
structur
dcsign
crd
complex
man
tetramannosid
care
examin
dcsign
bind
site
identifi
two
region
partial
exploit
nativ
ligand
could
use
increas
potenc
glycomimet
dcsign
antagonist
upon
hypothesi
design
synthes
small
focus
librari
mannos
glycoconjug
deriv
previous
publish
dcsign
antagonist
compound
test
use
dc
adhes
assay
mannanco
plate
result
demonstr
major
new
deriv
inhibit
dc
adhes
potent
order
magnitud
start
compound
addit
dock
studi
allow
qualit
ration
result
suggest
synthes
dcsign
antagonist
occupi
one
predict
bind
site
